| __timestamp | Gilead Sciences, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 9335772 |
| Thursday, January 1, 2015 | 3426000000 | 12390000 |
| Friday, January 1, 2016 | 3398000000 | 25602000 |
| Sunday, January 1, 2017 | 3878000000 | 21262000 |
| Monday, January 1, 2018 | 4056000000 | 28430000 |
| Tuesday, January 1, 2019 | 4381000000 | 40849000 |
| Wednesday, January 1, 2020 | 5151000000 | 60210000 |
| Friday, January 1, 2021 | 5246000000 | 83664000 |
| Saturday, January 1, 2022 | 5673000000 | 104097000 |
| Sunday, January 1, 2023 | 6090000000 | 106916000 |
| Monday, January 1, 2024 | 6091000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Gilead Sciences, a titan in the industry, has seen its SG&A expenses grow by over 100% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, Iovance Biotherapeutics, a burgeoning player, has experienced a staggering increase of over 1,000% in the same period, indicative of its aggressive growth strategy and scaling efforts. This comparison not only highlights the differing scales and strategies of these companies but also underscores the dynamic nature of the biotech sector. As Gilead consolidates its position, Iovance's rapid ascent is a testament to the potential of emerging biotech firms.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.